CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

human insulin

Last Updated: April 13, 2021
Result type: Reports
Project Number: SR0672-000
Product Line: Reimbursement Review

Generic Name: human insulin

Brand Name: Entuzity KwikPen

Manufacturer: Eli Lilly Canada Inc.

Therapeutic Area: Diabetes mellitus

Indications: ​To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.

Manufacturer Requested Reimbursement Criteria1: To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule C

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openDecember 22, 2020
Call for patient/clinician input closedFebruary 22, 2021
Clarification:

- Patient input submission received from Diabetes Canada

Submission receivedJanuary 27, 2021
Submission acceptedFebruary 10, 2021
Review initiatedFebruary 11, 2021
Draft CADTH review report(s) provided to sponsor for commentApril 30, 2021
Deadline for sponsors commentsMay 11, 2021
CADTH responses on draft review report(s) provided to sponsorJune 04, 2021
Expert committee meeting (initial)June 16, 2021
Draft recommendation issued to sponsorJune 28, 2021
To
June 30, 2021